Search Results

RedHill Biopharma Ltd. investors for the purchase and sale of 10,000,000 of the Company’s American Depositary Shares (“ADSs”) at a purchase price of $0.80 per ADS, in a registered direct offering.

RedHill Biopharma Ltd. announced that it has entered into definitive agreements with private investors for the purchase and sale, at a premium, of 2,144,487 of the Company’s American Depositary Shares, each ADS representing four hundred ordinary shares, par value NIS 0.01 per share, of the Company, and warrants to purchase up to an aggregate of 2,144,487ADSs, at a purchase price of $0.58289 per ADS and accompanying warrant, in a registered direct offering.

RedHill Biopharma Ltd. announced that it has closed its previously announced registered direct offering for the purchase and sale of 10,000,000 of the Company’s American Depositary Shares, each ADS representing four hundred ordinary shares, at a purchase price of $0.80 per ADS.

From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC to transfer the listing of the American Depositary Shares to the Nasdaq Capital Market.

RedHill Biopharma Ltd. today announced that it received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).

RedHill Biopharma Ltd. (NASDAQ: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, announced that the U.S. FDA (U.S. Food and Drug Administration) has granted five years’ market exclusivity for Talicia.

RedHill Biopharma Ltd. announced the issue of a new Chinese patent notice of allowance for opaganib in combination with immune checkpoint inhibitors as a method of inducing an anti-cancer immune response, providing protection for opaganib’s potential use with a range of approved and in-development immune checkpoint inhibitors across a growing range of indications through 2040.

RedHill Biopharma Ltd. announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes’ U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication from the Chinese National Intellectual Property Administration, valid through 2035.